Until recently, we were focused on the research and development of novel therapeutics for neurodegenerative diseases, such as Niemann Pick disease type C (NPC).
In May 2022, substantially all our assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc.
Orphazyme A/S Company announcement No. 33/2022 www.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, June 29, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the
Orphazyme A/S Company announcement No. 32/2022 www.orphazyme.com Company Registration No. 32266355 NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”) EVIDENCED BY AMERICAN
Orphazyme A/S Company announcement No. 30/2022 Annual report www.orphazyme.com Company Registration No. 32266355
